Literature DB >> 22125706

Colon targeted drug delivery systems: a review on primary and novel approaches.

Anil K Philip1, Betty Philip.   

Abstract

The colon is a site where both local and systemic delivery of drugs can take place. Local delivery allows topical treatment of inflammatory bowel disease. However, treatment can be made effective if the drugs can be targeted directly into the colon, thereby reducing the systemic side effects. This review, mainly compares the primary approaches for CDDS (Colon Specific Drug Delivery) namely prodrugs, pH and time dependent systems, and microbially triggered systems, which achieved limited success and had limitations as compared with newer CDDS namely pressure controlled colonic delivery capsules, CODESTM, and osmotic controlled drug delivery which are unique in terms of achieving in vivo site specificity, and feasibility of manufacturing process.

Entities:  

Year:  2010        PMID: 22125706      PMCID: PMC3215502          DOI: 10.5001/omj.2010.24

Source DB:  PubMed          Journal:  Oman Med J        ISSN: 1999-768X


  55 in total

1.  Development of pectin matrix tablets for colonic delivery of model drug ropivacaine.

Authors:  S F Ahrabi; G Madsen; K Dyrstad; S A Sande; C Graffner
Journal:  Eur J Pharm Sci       Date:  2000-03       Impact factor: 4.384

Review 2.  Pulsatile drug-delivery systems.

Authors:  T Bussemer; I Otto; R Bodmeier
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2001       Impact factor: 4.889

3.  Evaluation of an intestinal pressure-controlled colon delivery capsules prepared by a dipping method.

Authors:  Y I Jeong; T Ohno; Z Hu; Y Yoshikawa; N Shibata; S Nagata; K Takada
Journal:  J Control Release       Date:  2001-04-02       Impact factor: 9.776

4.  Asymmetric membrane in membrane capsules: a means for achieving delayed and osmotic flow of cefadroxil.

Authors:  Anil K Philip; Kamla Pathak; Pragati Shakya
Journal:  Eur J Pharm Biopharm       Date:  2007-12-23       Impact factor: 5.571

5.  Evidence for the delivery of narcotic antagonists to the colon as their glucuronide conjugates.

Authors:  J W Simpkins; M Smulkowski; R Dixon; R Tuttle
Journal:  J Pharmacol Exp Ther       Date:  1988-01       Impact factor: 4.030

6.  Colon-specific delivery of budesonide with azopolymer-coated pellets: therapeutic effects of budesonide with a novel dosage form against 2,4,6-trinitrobenzenesulphonic acid-induced colitis in rats.

Authors:  H Tozaki; T Fujita; J Komoike; S I Kim; H Terashima; S Muranishi; S Okabe; A Yamamoto
Journal:  J Pharm Pharmacol       Date:  1999-03       Impact factor: 3.765

7.  Calcium alginate beads as core carriers of 5-aminosalicylic acid.

Authors:  S Y Lin; J W Ayres
Journal:  Pharm Res       Date:  1992-09       Impact factor: 4.200

8.  Azo polymeric hydrogels for colon targeted drug delivery.

Authors:  K L Shantha; P Ravichandran; K P Rao
Journal:  Biomaterials       Date:  1995-11       Impact factor: 12.479

9.  Glucocorticoid-dextran conjugates as potential prodrugs for colon-specific delivery: hydrolysis in rat gastrointestinal tract contents.

Authors:  A D McLeod; D R Friend; T N Tozer
Journal:  J Pharm Sci       Date:  1994-09       Impact factor: 3.534

10.  Optimized prodrug approach: a means for achieving enhanced anti-inflammatory potential in experimentally induced colitis.

Authors:  Anil K Philip; Sunny Dabas; Kamla Pathak
Journal:  J Drug Target       Date:  2009-04       Impact factor: 5.121

View more
  45 in total

Review 1.  Oral bioavailability: issues and solutions via nanoformulations.

Authors:  Kamla Pathak; Smita Raghuvanshi
Journal:  Clin Pharmacokinet       Date:  2015-04       Impact factor: 6.447

2.  Enteric trimethyl chitosan nanoparticles containing hepatitis B surface antigen for oral delivery.

Authors:  Asma Farhadian; Naser Mohammadpour Dounighi; Mohammadreza Avadi
Journal:  Hum Vaccin Immunother       Date:  2015-07-09       Impact factor: 3.452

3.  Study and Understanding Behavior of Alginate-Inulin Synbiotics Beads for Protection and Delivery of Antimicrobial-Producing Probiotics in Colonic Simulated Conditions.

Authors:  Abdelbasset Atia; Ahmed Gomaa; Benoit Fernandez; Muriel Subirade; Ismail Fliss
Journal:  Probiotics Antimicrob Proteins       Date:  2018-06       Impact factor: 4.609

4.  Biopharmaceutical Evaluation and CMC Aspects of Oral Modified Release Formulations.

Authors:  Rong-Kun Chang; Neil Mathias; Munir A Hussain
Journal:  AAPS J       Date:  2017-07-05       Impact factor: 4.009

5.  Development of pH-sensitive pectinate/alginate microspheres for colon drug delivery.

Authors:  Fu-Yin Hsu; Ding-Syuan Yu; Chun-Chiang Huang
Journal:  J Mater Sci Mater Med       Date:  2012-10-27       Impact factor: 3.896

Review 6.  Potential applications of hydrophobically modified inulin as an active ingredient in functional foods and drugs - A review.

Authors:  Muhammad Usman; Chengnan Zhang; Prasanna Jagannath Patil; Arshad Mehmood; Xiuting Li; Muhammad Bilal; Junaid Haider; Shabbir Ahmad
Journal:  Carbohydr Polym       Date:  2020-10-06       Impact factor: 9.381

Review 7.  Progressing from Recurring Tissue Injury to Genomic Instability: A New Mechanism of Neutrophil Pathogenesis.

Authors:  Triet M Bui; Ronen Sumagin
Journal:  DNA Cell Biol       Date:  2019-06-12       Impact factor: 3.311

Review 8.  Colon-targeted oral drug delivery systems: design trends and approaches.

Authors:  Seth Amidon; Jack E Brown; Vivek S Dave
Journal:  AAPS PharmSciTech       Date:  2015-06-13       Impact factor: 3.246

Review 9.  Micro/nanofabricated platforms for oral drug delivery.

Authors:  Cade B Fox; Jean Kim; Long V Le; Cameron L Nemeth; Hariharasudhan D Chirra; Tejal A Desai
Journal:  J Control Release       Date:  2015-08-02       Impact factor: 9.776

10.  Budesonide-Loaded Pectin/Polyacrylamide Hydrogel for Sustained Delivery: Fabrication, Characterization and In Vitro Release Kinetics.

Authors:  Manisha Pandey; Hira Choudhury; Sahleni Kaur D/O Segar Singh; Naveenya Chetty Annan; Subrat Kumar Bhattamisra; Bapi Gorain; Mohd Cairul Iqbal Mohd Amin
Journal:  Molecules       Date:  2021-05-05       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.